771 related articles for article (PubMed ID: 23745526)
1. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler.
Mahler DA; Waterman LA; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):174-9. PubMed ID: 23025451
[TBL] [Abstract][Full Text] [Related]
3. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
6. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
[TBL] [Abstract][Full Text] [Related]
8. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
9. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
Cazzola M; Paggiaro P; Palange P; Bjermer L; Ausin P; Carlsson LG; Ekelund J; Lotvall J
Clin Drug Investig; 2012 Mar; 32(3):147-55. PubMed ID: 22235841
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[TBL] [Abstract][Full Text] [Related]
11. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
13. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
14. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.
Bollu V; Ernst FR; Karafilidis J; Rajagopalan K; Robinson SB; Braman SS
Int J Chron Obstruct Pulmon Dis; 2013; 8():631-9. PubMed ID: 24353413
[TBL] [Abstract][Full Text] [Related]
15. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.
Hanrahan JP; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Baumgartner RA
COPD; 2008 Feb; 5(1):25-34. PubMed ID: 18259972
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.
Quinn D; Seale JP; Reisner C; Fischer T; Golden M; Fernandez C; Darken P; St Rose E; Thomas M; Tardie G; Orevillo C
Respir Med; 2014 Sep; 108(9):1327-35. PubMed ID: 25060541
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
[TBL] [Abstract][Full Text] [Related]
18. Bronchodilator response of advanced lung function parameters depending on COPD severity.
Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
[TBL] [Abstract][Full Text] [Related]
19. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
20. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
